211 patents currently held
43 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
29
Ending by 2030
Feb 2027
Next term end
162
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2028 · High confidence
Also notable
Ends no later than Jul 2030 · Medium confidence
Also notable
Ends Mar 2033 · High confidence
Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections
US 7,951,789
Cited by 70 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Compounds Useful for Treating Aids
US 9,145,367
Cited by 52 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Targeted Human-Interferon Fusion Proteins
US 9,492,562
Cited by 47 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Formerly held, still cited
Notable
Ends no later than Sep 2028 · Medium confidence
The most cited patent in this portfolio, cited by 191 later US patents, top 5% of utility patents granted in 2009 in our data. Protection runs to 2028. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Idenix Pharmaceuticals LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 26, 2026The maintenance fee for Programmable Volatile/Non-Volatile Memory Cell (US 9,042,157) comes due Nov 26, 2026. Unpaid by May 26, 2027, it lapses early.
- 5 fees due Dec 9 to 25, 2026 · next Dec 9
- 4 fees due Jan 4 to 28, 2027 · next Jan 4
- 5 fees due Feb 18 to 28, 2027 · next Feb 18
- 8 fees due Mar 1 to 29, 2027 · next Mar 1
- 3 fees due Apr 8 to 22, 2027 · next Apr 8
- 3 fees due May 7 to 28, 2027 · next May 7
- 4 fees due Jun 15 to 29, 2027 · next Jun 15
- 3 fees due Jul 7 to 21, 2027 · next Jul 7
- 4 fees due Aug 2 to 27, 2027 · next Aug 2
- 2 fees due Sep 29 to 30, 2027 · next Sep 29
- 2 fees due Oct 12 to 21, 2027 · next Oct 12
- 2 fees due Nov 5 to 14, 2027 · next Nov 5
Recent changes
- 5 of the patents on this record were granted since Aug 19, 2026
- 5 terms have ended since Aug 19, 2026
What they patent
The 5 largest of its 162 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compounds Useful for Treating Aids | 8 in force | to Jul 2030 |
| Targeted Modified TNF Family Members | 6 in force | to Jul 2034 |
| Quinoline Derivatives for the Treatment of Inflammatory Diseases | 5 in force | to Jul 2035 |
| Targeting of Human Interferon Antagonists | 4 in force | to Oct 2037 |
| Targeted Human-Interferon Fusion Proteins | 4 in force | to Mar 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,785,577 | Peptides or Peptidic Conjugate Derivatives of MSH and the Use Thereof for Cosmetically Fighting Against Canities In force · High confidence | In force | High confidence | |
| US 9,249,173 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections In force · Medium confidence | In force | Medium confidence | |
| US 8,017,581 | Msh-Agonist Tripeptide Conjugates In force · High confidence | In force | High confidence | |
| US 7,951,789 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections held by Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique and Universite Montpellier II In force · High confidence | In force | High confidence | |
| US 7,989,467 | Use of Indole-Derived Compounds for the Preparation of a Medicament That Can Be Used to Treat Diseases Related to the Splicing Process In force · High confidence | In force | High confidence | |
| US 8,062,561 | Negative Electrode Composite Material, Production Method, Negative Electrode and Lithium-Ion Battery held by Centre National d'Etudes Spatiales, Centre National de la Recherche Scientifique and Universite de Montpellier II In force · High confidence | In force | High confidence | |
| US 7,902,202 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections held by Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique and Universite Montpellier II In force · High confidence | In force | High confidence | |
| US 10,130,595 | Chemical Molecules That Inhibit the Slicing Mechanism for Treating Diseases Resulting from Splicing Anomalies In force · High confidence | In force | High confidence | |
| US 10,654,813 | Chemical Molecules That Inhibit the Slicing Mechanism for Treating Diseases Resulting from Splicing Anomalies In force · High confidence | In force | High confidence | |
| US 9,233,931 | Chemical Molecules That Inhibit the Slicing Mechanism for Treating Diseases Resulting from Splicing Anomalies In force · High confidence | In force | High confidence |
Also on record, not counted in the 211: 43 patents in force now held by others · 114 patents ended · 140 applications pending · 152 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.